Present status of the use of recombinant human TSH in thyroid cancer management
Author:
Open Access
- 1 January 2006
- journal article
- research article
- Published by Medical Journals Sweden AB in Acta Oncologica
- Vol. 45 (8) , 1018-1030
Abstract
(2006). Present status of the use of recombinant human TSH in thyroid cancer management. Acta Oncologica: Vol. 45, No. 8, pp. 1018-1030.Keywords
This publication has 49 references indexed in Scilit:
- Juvenile differentiated thyroid carcinoma and the role of radioiodine in its treatment: a qualitative reviewEndocrine-Related Cancer, 2005
- Lack of Efficacy of Recombinant Human Thyrotropin Versus Thyroid Hormone Withdrawal for Radioiodine Therapy Imaging in a Patient with Differentiated Thyroid Carcinoma Lung MetastasesThyroid®, 2004
- Subcutaneous Administration of Recombinant Human Thyrotropin as an Alternative to Thyroid Hormone Withdrawal in Patients with Anticoagulated Thyroid Cancer: Preliminary ResultsThyroid®, 2004
- Quality of life and psychometric functionality in patients with differentiated thyroid carcinoma.Endocrine-Related Cancer, 2003
- Near-Lethal Respiratory Failure After Recombinant Human Thyroid-Stimulating Hormone Use in a Patient with Metastatic Thyroid CarcinomaThyroid®, 2003
- Usefulness of Recombinant Human Thyrotropin in the Radiometabolic Treatment of Selected Patients with Thyroid CancerThyroid®, 2001
- Malignant Struma Ovarii: An Unusual PresentationThyroid®, 2001
- Using Recombinant Human TSH in the Management of Well-Differentiated Thyroid Cancer: Current Strategies and Future DirectionsThyroid®, 2000
- Isolated Thyrotropin Deficiency Secondary to Primary Empty Sella in a Patient with Differentiated Thyroid Carcinoma: An Indication for Recombinant ThyrotropinThyroid®, 1999
- Papillary and Follicular Thyroid CarcinomaNew England Journal of Medicine, 1998